Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
9.61
-0.07 (-0.72%)
Oct 28, 2025, 11:42 AM EDT - Market open
Personalis Revenue
Personalis had revenue of $17.20M in the quarter ending June 30, 2025, a decrease of -23.81%. This brings the company's revenue in the last twelve months to $80.32M, up 0.36% year-over-year. In the year 2024, Personalis had annual revenue of $84.61M with 15.15% growth.
Revenue (ttm)
$80.32M
Revenue Growth
+0.36%
P/S Ratio
9.34
Revenue / Employee
$350,729
Employees
229
Market Cap
852.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PSNL News
- 6 days ago - Personalis to Announce Third Quarter 2025 Financial Results - Business Wire
- 12 days ago - Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing - Business Wire
- 6 weeks ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test - Business Wire
- 7 weeks ago - Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing - Business Wire
- 2 months ago - Personalis to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 2 months ago - Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript - Seeking Alpha